Literature DB >> 15780196

Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain.

Xian-hui He1, Li-hui Xu, Yi Liu.   

Abstract

AIM: To investigate the expression and regulation of PD-1 ligand 1 (PD-L1) in peripheral blood mononuclear cells (PBMC).
METHODS: The cDNA encoding human PD-L1 precursor was cloned from the total RNA extracted from the resting and phorbol dibutyrate plus ionomycin- or phytohemagglutinin-activated PBMC, by reverse transcription polymerase chain reaction (RT-PCR), and independent clones were sequenced and analyzed. The expression and subcellular localization were examined in transiently transfected cells. The PD-L1 gene expression in different PBMC was also analyzed by RT-PCR.
RESULTS: A novel human PD-L1 splice variant was identified from the activated PBMC. It was generated by splicing out exon? encoding an immunoglobulin variable domain (Igv)-like domain but retaining all other exons without a frame-shift. Consequently, the putative translated protein contained all other domains including the transmembrane region except for the Igv-like domain. Furthermore, the conventional isoform was expressed on the plasma surface whereas the novel isoform showed a pattern of intracellular membrane distribution in transiently transfected K562 cells. In addition, the expression pattern of the PD-L1 splice variant was variable in different individuals and in different cellular status.
CONCLUSION: PD-L1 expression may be regulated at the posttranscriptional level through alternative splicing, and modulation of the PD-L1 isoform expression may influence the outcome of specific immune responses in the peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780196     DOI: 10.1111/j.1745-7254.2005.00086.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  25 in total

1.  Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Authors:  Jun Zhou; Kathleen M Mahoney; Anita Giobbie-Hurder; Fengmin Zhao; Sandra Lee; Xiaoyun Liao; Scott Rodig; Jingjing Li; Xinqi Wu; Lisa H Butterfield; Matthias Piesche; Michael P Manos; Lauren M Eastman; Glenn Dranoff; Gordon J Freeman; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2017-05-18       Impact factor: 11.151

2.  Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.

Authors:  Vassil Dimitrov; Manuella Bouttier; Giselle Boukhaled; Reyhaneh Salehi-Tabar; Radu G Avramescu; Babak Memari; Benedeta Hasaj; Gergely L Lukacs; Connie M Krawczyk; John H White
Journal:  J Biol Chem       Date:  2017-10-23       Impact factor: 5.157

Review 3.  Programmed death ligand 1 signals in cancer cells.

Authors:  Anand V R Kornepati; Ratna K Vadlamudi; Tyler J Curiel
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 60.716

Review 4.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

5.  Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion.

Authors:  Xue Pan; Anyuan Zhong; Yufei Xing; Minhua Shi; Bin Qian; Tong Zhou; Yongjing Chen; Xueguang Zhang
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

Review 6.  Soluble immune checkpoints in cancer: production, function and biological significance.

Authors:  Daqian Gu; Xiang Ao; Yu Yang; Zhuo Chen; Xiang Xu
Journal:  J Immunother Cancer       Date:  2018-11-27       Impact factor: 13.751

7.  27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Authors:  Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson
Journal:  Cancer Lett       Date:  2020-08-28       Impact factor: 8.679

Review 8.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.

Authors:  Bor-Chyuan Su; Chen-Hung Ting; Kang-Yun Lee; Sheng-Ming Wu; Po-Hao Feng; Yao-Fei Chan; Jyh-Yih Chen
Journal:  Histol Histopathol       Date:  2020-10-28       Impact factor: 2.303

10.  Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.

Authors:  Nattawat Onlamoon; Kenneth Rogers; Ann E Mayne; Kovit Pattanapanyasat; Kazuyasu Mori; Francois Villinger; Aftab A Ansari
Journal:  Immunology       Date:  2008-02-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.